Baek H, Yang S, Kim S, Lee Y, Park H, Park M
Int J Mol Sci. 2025; 26(5).
PMID: 40076949
PMC: 11901132.
DOI: 10.3390/ijms26052329.
Garavaglia B, Vallino L, Ferraresi A, Amoruso A, Pane M, Isidoro C
Biomedicines. 2025; 13(2).
PMID: 40002754
PMC: 11853712.
DOI: 10.3390/biomedicines13020339.
Gkiokas A, Papadatou-Gigante M, Gkioka A, Koudouna A, Tryfou T, Alexandropoulos A
Cells. 2025; 14(4).
PMID: 39996747
PMC: 11853255.
DOI: 10.3390/cells14040275.
Wellhausen J, Rohl L, Berszin M, Krucken I, Zebralla V, Pirlich M
Front Immunol. 2025; 15:1473897.
PMID: 39882242
PMC: 11774711.
DOI: 10.3389/fimmu.2024.1473897.
Wang Q, Yu M, Zhang S
Front Immunol. 2025; 15:1440830.
PMID: 39877377
PMC: 11772360.
DOI: 10.3389/fimmu.2024.1440830.
Biological Roles and Clinical Therapeutic Applications of Tumor-Associated Macrophages in Colorectal Liver Metastasis.
Li S, Hao L, Hu X
J Inflamm Res. 2024; 17:8429-8443.
PMID: 39529996
PMC: 11552512.
DOI: 10.2147/JIR.S493656.
Targeting of TAMs: can we be more clever than cancer cells?.
Kzhyshkowska J, Shen J, Larionova I
Cell Mol Immunol. 2024; 21(12):1376-1409.
PMID: 39516356
PMC: 11607358.
DOI: 10.1038/s41423-024-01232-z.
Investigating tumor immunogenicity in breast cancer: deciphering the tumor immune response to enhance therapeutic approaches.
Naji O, Ghouzlani A, Rafii S, Sadiqi R, Kone A, Harmak Z
Front Immunol. 2024; 15:1399754.
PMID: 39507526
PMC: 11538072.
DOI: 10.3389/fimmu.2024.1399754.
Role of disulfidptosis in colorectal adenocarcinoma: implications for prognosis and immunity.
Yang R, Lai C, Huang L, Li F, Peng W, Wu M
Front Immunol. 2024; 15:1409149.
PMID: 39399504
PMC: 11466812.
DOI: 10.3389/fimmu.2024.1409149.
Tumor draining lymph nodes connected to cold triple-negative breast cancers are characterized by Th2-associated microenvironment.
Guo W, Tan J, Wang L, Egelston C, Simons D, Ochoa A
Nat Commun. 2024; 15(1):8592.
PMID: 39366933
PMC: 11452381.
DOI: 10.1038/s41467-024-52577-y.
M2 macrophage-derived lncRNA NORAD in EVs promotes NSCLC progression via miR-520g-3p/SMIM22/GALE axis.
Zhao Q, Li B, Zhang X, Zhao H, Xue W, Yuan Z
NPJ Precis Oncol. 2024; 8(1):185.
PMID: 39215037
PMC: 11364787.
DOI: 10.1038/s41698-024-00675-x.
An update to experimental and clinical aspects of tumor-associated macrophages in cancer development: hopes and pitfalls.
Salmaninejad A, Layeghi S, Falakian Z, Golestani S, Kobravi S, Talebi S
Clin Exp Med. 2024; 24(1):156.
PMID: 39003350
PMC: 11246281.
DOI: 10.1007/s10238-024-01417-w.
Targeted deletion of CD244 on monocytes promotes differentiation into anti-tumorigenic macrophages and potentiates PD-L1 blockade in melanoma.
Kim J, Kim T, Chae S, Ha H, Park Y, Park S
Mol Cancer. 2024; 23(1):45.
PMID: 38424542
PMC: 10903025.
DOI: 10.1186/s12943-024-01936-w.
Unveiling the mechanisms and challenges of cancer drug resistance.
Khan S, Fatima K, Aisha S, Malik F
Cell Commun Signal. 2024; 22(1):109.
PMID: 38347575
PMC: 10860306.
DOI: 10.1186/s12964-023-01302-1.
Inactivation of pentraxin 3 suppresses M2-like macrophage activity and immunosuppression in colon cancer.
Chen F, Wu Y, Cheng C, Hsiao Y, Chi J, Hung L
J Biomed Sci. 2024; 31(1):10.
PMID: 38243273
PMC: 10799366.
DOI: 10.1186/s12929-023-00991-7.
L3MBTL3 Is a Potential Prognostic Biomarker and Correlates with Immune Infiltrations in Gastric Cancer.
Gan L, Yang C, Zhao L, Wang S, Ye Y, Gao Z
Cancers (Basel). 2024; 16(1).
PMID: 38201555
PMC: 10778146.
DOI: 10.3390/cancers16010128.
A disulfidptosis-related lncRNAs signature in hepatocellular carcinoma: prognostic prediction, tumor immune microenvironment and drug susceptibility.
Liu Y, Meng J, Ruan X, Wei F, Zhang F, Qin X
Sci Rep. 2024; 14(1):746.
PMID: 38185671
PMC: 10772085.
DOI: 10.1038/s41598-024-51459-z.
A dynamic atlas of immunocyte migration from the gut.
Galvan-Pena S, Zhu Y, Hanna B, Mathis D, Benoist C
Sci Immunol. 2024; 9(91):eadi0672.
PMID: 38181094
PMC: 10964343.
DOI: 10.1126/sciimmunol.adi0672.
A novel endoplasmic reticulum stress-related lncRNA signature for prognosis prediction and immune response evaluation in Stomach adenocarcinoma.
Song Z, Su M, Li X, Xie J, Han F, Yao J
BMC Gastroenterol. 2023; 23(1):432.
PMID: 38066437
PMC: 10709857.
DOI: 10.1186/s12876-023-03001-0.
The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation.
Luo F, Li H, Ma W, Cao J, Chen Q, Lu F
Cell Mol Immunol. 2023; 21(1):60-79.
PMID: 38062129
PMC: 10757718.
DOI: 10.1038/s41423-023-01112-y.